Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment.
Cancer Invest
; 39(8): 627-644, 2021 Sep.
Article
en En
| MEDLINE
| ID: mdl-34254870
ABSTRACT
Glioblastoma (GB) is the most lethal form of primary brain neoplasm. TMZ is the first-line standard treatment, but the strong resistance constrains the efficacy in clinical use. GB contains glioma stem cells (GSCs), which contribute to TMZ resistance, promote cell survival evolvement, and repopulate the tumor mass. This review summarizes the TMZ-resistance mechanisms and discusses several potential therapies from the conservative opinion of GSC-targeted therapy orientation to the current view of TMZ resistance-aimed efficacy, which will provide an understanding of the role of heterogeneity in drug resistance and improve therapeutic efficacy in general.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Glioblastoma
/
Resistencia a Antineoplásicos
/
Antineoplásicos Alquilantes
/
Temozolomida
Límite:
Humans
Idioma:
En
Revista:
Cancer Invest
Año:
2021
Tipo del documento:
Article
País de afiliación:
China